TG Therapeutics: A Look at New Briumvi Data and Ocrevus Approval Zunovo (NASDAQ:TGTX)

This article was written by

Follow

Analyst Disclosure: We have/we have an advantageous long position in TGTX stock either through owning shares, options or other derivatives. I wrote this article myself and it expresses my own opinions. I receive no compensation for this (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

This article reflects the opinion of the author and should not be considered in any way as a recommendation to buy or sell or investment advice.

Looking for Alpha’s reveal: Past performance is no guarantee of future results. No recommendation or advice is given as to whether any investment is suitable for any particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, a US broker or investment adviser, or an investment bank. Our analysts are third-party authors that include both professional investors and individual investors who may not be authorized or certified by any institute or regulatory body.